Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN Horwitz, S. M., Ansell, S., Ai, W. Z., Barnes, J., Barta, S. K., Brammer, J., Clemens, M. W., Dogan, A., Foss, F., Ghione, P., Goodman, A. M., Guitart, J., Halwani, A., Haverkos, B. M., Hoppe, R. T., Jacobsen, E., Jagadeesh, D., Jones, A., Kallam, A., Kim, Y. H., Kumar, K., Mehta-Shah, N., Olsen, E. A., Rajguru, S. A., Rozati, S., Said, J., Shaver, A., Shea, L., Shinohara, M. M., Sokol, L., Torres-Cabala, C., Wilcox, R., Wu, P., Zain, J., Dwyer, M., Sundar, H. 2022; 20 (3): 285-308

Abstract

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma, anaplastic lymphoma kinase-negative, and enteropathy-associated T-cell lymphoma. This discussion section focuses on the diagnosis and treatment of PTCLs as outlined in the NCCN Guidelines for T-Cell Lymphomas.

View details for DOI 10.6004/jnccn.2022.0015

View details for PubMedID 35276674